Overcoming beta-agonist tolerance: High dose salbutamol and ipratropium bromide. Two randomised controlled trials

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Haney, Sarah ^a,b   Hancox, Robert J ^b,c  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b WAIKATO HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG COMBINATION; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG POTENTIATION; DRUG TOLERANCE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG TOLERANCE; FEMALE; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 47049090204     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-19     Document Type: Article

References (34)

1. Global strategy for asthma management and prevention. 2002, NIH publication no 96-3659A. Bethesda , Institute NIHNHLB, updated 2005.
2. BTS British guideline on the management of asthma. Thorax 2003, 58(suppl 1):1-83. BTS.
3. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic β2 adrenergic responses after regular twice daily treatment with eformeterol dry powder in asthmatic patients. Thorax 1995, 50:497-504. 7597661.
4. Cheung D, Timmers MC, Zwinderman AH, GBel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting β2-adrenocepter agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992, 327:1198-1203. 1357550.
5. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Town GI, Taylor DR. Tolerance to beta agonists during acute bronchoconstriction. Eur Respir J 1999, 14:283-287. 10.1034/j.1399-3003.1999.14b08.x, 10515402.
6. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance. Eur Respir J 2001, 17:368-373. 10.1183/09031936.01.17303680, 11405513.
7. Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM, Taylor DR. Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003, 21:810-815. 10.1183/09031936.03.00067503, 12765426.
8. Van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists. Thorax 2001, 56:529-535. 10.1136/thorax.56.7.529, 11413351.
9. Storms WW, Chervinsky P, Ghannam A, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to resuce bronchodilation after challenge. Respir Med 2004, 98:1051-1062. 10.1016/j.rmed.2004.05.008, 15526805.
10. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol 2003, 56:494-500. 10.1046/j.1365-2125.2003.01887.x, 14651722.
11. Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005, 99:566-571. 10.1016/j.rmed.2004.10.014, 15823453.
12. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respiratory Research 2005, 6:107. 1266400, 16168062, 10.1186/1465-9921-6-107.
13. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006, 31:181-196. 10.1385/CRIAI:31:2:181, 17085792.
14. Sears MR, Lotvall J. Past, present and future - β2-adrenoceptor agonists in asthma management. Respir Med 2005, 99:152-170. 10.1016/j.rmed.2004.07.003, 15715182.
15. Rodrigo G, Rodrigo C. The role of anticholinergics in acute asthma treatment. Chest 2002, 121:1977-1987. 10.1378/chest.121.6.1977, 12065366.
16. Giembycz MA, Newton R. Beyond the dogma: novel β2-adrenoceptor signalling in the airways. Eur Respir J 2006, 27(6):1286-1306. 10.1183/09031936.06.00112605, 16772391.
17. Sarria B, Naline E, Zhang Y, Cortijo J, Molimard M, Moreau J, Therond P, Advernier C, Morcillo EJ. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. American Journal of Lung Cell Molecular Physiology 2002, 283:L1125-L1132.
18. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995, 96:44-49. 10.1016/S0091-6749(95)70031-5, 7622762.
19. Hancox RJ, Subbarao P, Kamada D, Watson R, Hargreave FE, Inman MD. Beta 2 agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002, 165:1068-1070.
20. Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983, 38:760-765.
21. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo JL. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993, 6:53-83.
22. Colacone A, Afilalo M, Wolkove N, Kreisman H. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest 1993, 104:835-841.
23. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000, 161(6):1862-1868.
24. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999, 107:209-213. 10.1016/S0002-9343(99)00222-3, 10492312.
25. Windom HH, Burgess CD, Crane J, Pearce N, Kwong T, Beasley R. The self-administration of inhaled beta agonist drugs during severe asthma. N Z Med J 1990, 103:205-207.
26. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signalling in the pathophysiology of asthma and COPD. Respiratory Research 2006, 7:73. 1479816, 16684353, 10.1186/1465-9921-7-73.
27. Watson N, Magnussen H, Rabe KF. Antagonism of β-adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol. Eur J Pharmacol 1995, 275:307-310. 10.1016/0014-2999(95)00048-P, 7768300.
28. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995, 152:838-860.
29. Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981, 36:523-529.
30. Dollery C. Therapeutic Drugs: formoterol. Therapeutic Drugs 1999, F155-F158. Churchill Livingstone, Dollery C, 2.
31. Brodde OE, Daul A, Michel-Reher M, Boosma F, Man in't Veld AJ, Schlieper P, Michel MC. Agonist-induced desensitization of β-adrenoceptor function in humans. Circulation 1990, 81:914-921. 1968366.
32. Hancox RJ. Interactions between corticosteroids and β2-agonists. Clin Rev Allergy Immunol 2006, 31:231-246. 10.1385/CRIAI:31:2:231, 17085796.
33. Lee DKC, Jackson CM, Bates CE, Lipworth BJ. Cross tolerance to salbutamol occurs independently of β2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax 2004, 59:662-667. 10.1136/thx.2003.019059, 15282385.
34. Makker HK, Holgate ST. Relation of the hypertonic saline responsiveness of the airways to exercise induced asthma symptom severity and to histamine or methacholine reactivity. Thorax 1993, 48:142-147.